Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Apr;30(4):285-290.
doi: 10.1080/13543784.2021.1880565. Epub 2021 Feb 2.

Key challenges for drugs in clinical development for cholangiocarcinoma

Affiliations
Editorial

Key challenges for drugs in clinical development for cholangiocarcinoma

Bridget P Keenan et al. Expert Opin Investig Drugs. 2021 Apr.
No abstract available

PubMed Disclaimer

Similar articles

Cited by

References

    1. Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95–111. - PMC - PubMed
    1. Saha SK, Zhu AX, Fuchs CS, et al. Forty-year trends in cholangiocarcinoma Incidence in the U.S.: intrahepatic disease on the rise. Oncologist. 2016;21(5):594–599. - PMC - PubMed
    1. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–588. - PMC - PubMed
    2. •• This is a very comprehensive review of the etiology, biology, and management of cholangiocarcinom, covering the spectrum of basic science to clinical knowledge.

    1. Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71(1):104–114. - PubMed
    1. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources